Prenatal exposure to glucocorticoids was associated with an increased risk of some mental disorders at age 15, according to a study published in JAMA Network Open.
Prenatal exposure to glucocorticoids was associated with an increased risk of some mental disorders at age 15, according to a study published in JAMA Network Open.
Loudness of snoring, regardless of hypoxic burden and obstructive sleep apnea syndrome severity (OSAS), may contribute to hyperactivity in pediatric patients, according to an observational prospective study published in Sleep Medicine.
Loudness of snoring, regardless of hypoxic burden and obstructive sleep apnea syndrome severity (OSAS), may contribute to hyperactivity in pediatric patients, according to an observational prospective study published in Sleep Medicine.
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
Treatment-resistant depression (TRD) may be a more complex and multifaceted condition than previously thought, with authors of a recent study calling for a “unified definition and reconceptualization” of the illness. Their findings were...
Treatment-resistant depression (TRD) may be a more complex and multifaceted condition than previously thought, with authors of a recent study calling for a “unified definition and reconceptualization” of the illness. Their findings were...
The prevalence of OUD diagnoses increased from 2005 to 2017, peaked in 2017, and then declined until 2022, according to a recent cross-sectional study of national Veterans Health Administration (VHA) electronic health record data published in...
The prevalence of OUD diagnoses increased from 2005 to 2017, peaked in 2017, and then declined until 2022, according to a recent cross-sectional study of national Veterans Health Administration (VHA) electronic health record data published in...
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
A small group of patients with OUD developed buprenorphine-precipitated withdrawal (PW) in emergency department or hospital settings, according to recent retrospective cohort study results published in JAMA Network Open.
A small group of patients with OUD developed buprenorphine-precipitated withdrawal (PW) in emergency department or hospital settings, according to recent retrospective cohort study results published in JAMA Network Open.
A recent meta-analysis questions the effectiveness of transcranial direct current stimulation (tDCS) for improving cognitive impairments in individuals with schizophrenia after finding no statistically significant difference in cognitive...
A recent meta-analysis questions the effectiveness of transcranial direct current stimulation (tDCS) for improving cognitive impairments in individuals with schizophrenia after finding no statistically significant difference in cognitive...
Join Dr Rakesh Jain and Dr Craig Chepke for an insightful and heartfelt conversation in the inaugural Psych Congress Family & Friends Podcast. A discussion of feelings surrounding the recent passing of Dr Vladimir Maletic leads to an...
Join Dr Rakesh Jain and Dr Craig Chepke for an insightful and heartfelt conversation in the inaugural Psych Congress Family & Friends Podcast. A discussion of feelings surrounding the recent passing of Dr Vladimir Maletic leads to an...
Schizophrenia Knowledge Base is a new online resource for healthcare professionals dedicated to advancing the understanding of schizophrenia. Dive into comprehensive content on the latest research in symptomology, prevalence, treatment challenges, and evolving therapies. Start learning today!
It's important to understand the prevalence and clinical presentation of negative symptoms and cognitive impairment in people living with schizophrenia. Watch now!
This year, NP Psych Navigator will provide new resources and evidence-based, patient-centered disease education. Explore today to enhance your knowledge and support your patients living with MDD and BP-1.
ABBV-US-01827-MC, V1.0 | Approved 12/2024 | AbbVie Medical Affairs
More patients with schizophrenia are covered by Medicare and Medicaid compared with commercial payers in the United States, according to results from a 2022 claims analysis presented in a poster at Psych Congress.
“Among the Medicaid...
More patients with schizophrenia are covered by Medicare and Medicaid compared with commercial payers in the United States, according to results from a 2022 claims analysis presented in a poster at Psych Congress.
“Among the Medicaid...
Rebecca Barbee, MSPAS, PA-C, CAQ-Psych, explains the differences between dystonia, akathisia, drug-induced Parkinsonism, and tardive dyskinesia, as well as the different management approaches for each.
Rebecca Barbee, MSPAS, PA-C, CAQ-Psych, explains the differences between dystonia, akathisia, drug-induced Parkinsonism, and tardive dyskinesia, as well as the different management approaches for each.
Patients living with schizophrenia discussed cognitive symptoms of the disease less often than psychotic symptoms, cognitive and other negative symptoms were “perceived” as “equally burdensome” as the positive symptoms of the disease due to...
Patients living with schizophrenia discussed cognitive symptoms of the disease less often than psychotic symptoms, cognitive and other negative symptoms were “perceived” as “equally burdensome” as the positive symptoms of the disease due to...
In this video, Craig Chepke, MD, DFAPA, scientific director, Psych Congress, explains the vital differences between dopamine D2 receptor antipsychotics and muscarinic agonists for the treatment of schizophrenia, including mechanisms of action...
In this video, Craig Chepke, MD, DFAPA, scientific director, Psych Congress, explains the vital differences between dopamine D2 receptor antipsychotics and muscarinic agonists for the treatment of schizophrenia, including mechanisms of action...
A rstudy presented in a poster at Psych Congress 2024 in Boston, Massachusetts, aimed to understand the characteristics and treatment patterns of patients with MDD who experience prominent anhedonia compared to those who do not or who have...
A rstudy presented in a poster at Psych Congress 2024 in Boston, Massachusetts, aimed to understand the characteristics and treatment patterns of patients with MDD who experience prominent anhedonia compared to those who do not or who have...
A qualitative study involving unpaid and professional caregivers of patients with schizophrenia confirmed the content and usability of the Schizophrenia Cognition Rating Scale (SCoRS).
A qualitative study involving unpaid and professional caregivers of patients with schizophrenia confirmed the content and usability of the Schizophrenia Cognition Rating Scale (SCoRS).
Watch these exclusive insights with Desiree Matthews, PMHNP-BC, to learn how this novel treatment could reshape the landscape of care for adults living with schizophrenia.
Watch these exclusive insights with Desiree Matthews, PMHNP-BC, to learn how this novel treatment could reshape the landscape of care for adults living with schizophrenia.
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
The US Food and Drug Administration has issued a highly-anticipated decision: the approval of donanemab—to be marketed as Kisunla by manufacturer Eli Lilly—for the treatment of early Alzheimer disease.
The US Food and Drug Administration has issued a highly-anticipated decision: the approval of donanemab—to be marketed as Kisunla by manufacturer Eli Lilly—for the treatment of early Alzheimer disease.
The US Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults.
The US Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults.
Dr Craig Chepke discusses the importance of routine screening and monitoring for tardive dyskinesia (TD) in assessing disease severity, determining impact, and selecting treatment strategies.
Dr Craig Chepke discusses the importance of routine screening and monitoring for tardive dyskinesia (TD) in assessing disease severity, determining impact, and selecting treatment strategies.
Join Dr Rakesh Jain and Dr Craig Chepke for an insightful and heartfelt conversation in the inaugural Psych Congress Family & Friends Podcast. A discussion of feelings surrounding the recent passing of Dr Vladimir Maletic leads to an...
Join Dr Rakesh Jain and Dr Craig Chepke for an insightful and heartfelt conversation in the inaugural Psych Congress Family & Friends Podcast. A discussion of feelings surrounding the recent passing of Dr Vladimir Maletic leads to an...
Introducing our new psychiatry and psychopharmacology podcast aimed at enhancing your clinical practice in an approachable and heartfelt way, hosted by Rakesh Jain, MD, MPH, and Craig Chepke, MD, DFAPA. Subscribe now!
Introducing our new psychiatry and psychopharmacology podcast aimed at enhancing your clinical practice in an approachable and heartfelt way, hosted by Rakesh Jain, MD, MPH, and Craig Chepke, MD, DFAPA. Subscribe now!
Gain essential strategies for identifying and managing postpartum depression (PPD). Our latest guide provides in-depth insights to help you offer the best care for mothers facing PPD.
The Rapid Mood Screener site offers the Patient Case Navigator, an interactive tool that can help clinicians learn how to differentiate between BP-1 and MDD. This tool allows you to test your knowledge as you review an engaging patient case, which may help you accurately screen patients in your practice.
ABBV-US-01837-MC, V1.0 | Approved 12/2024 | AbbVie Medical Affairs
Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN
Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.